Johnson & Johnson announced that TREMFYA (guselkumab) met primary and major secondary endpoints in the Phase 4 STAR study, showing significant improvement in axial symptoms and MRI-confirmed inflammation in biologic-naïve adults with active psoriatic arthritis and axial involvement. This is the first study to use MRI to objectively confirm axial inflammation and demonstrate its reduction. The results support TREMFYA as a first-line treatment option to help stop joint damage in this patient group. Detailed findings will be presented at an upcoming scientific congress.
Johnson & Johnson's stock price is currently USD 270.74 on Pluang as of Sep 25, 2026 18:42 WIB, showing a slight 0.02% increase in the last day. The company holds a substantial market cap of $652.31 billion, reflecting its significant presence in the health sector. Despite the positive news, Pluang order activity leans heavily towards selling, with 85% of orders to sell and only 15% to buy at this time.
Johnson & Johnson announced long-term results from the Phase 2 CARTITUDE-2 study showing that 50% of multiple myeloma patients treated early with a single CARVYKTI infusion remained alive and progression-free for at least five years without maintenan...
Retirees deciding between federally insured CDs and dividend stocks must consider yield stability versus growth potential. CDs offer fixed interest rates, currently averaging 1.73% nationally, with FDIC insurance protecting principal up to $250,000. ...
Johnson & Johnson announced data from the Phase 3 MajesTEC-3 trial showing that combining TECVAYLI with DARZALEX FASPRO significantly improves survival in relapsed or refractory multiple myeloma patients. About 87% of treated patients had mortality r...
